These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Identification of human T cell hybridoma-derived macrophage activating factor as interleukin-2.
    Author: Higashi N, Higuchi M, Hanada N, Oeda J, Kobayashi Y, Osawa T.
    Journal: J Biochem; 1993 Jun; 113(6):715-20. PubMed ID: 8370669.
    Abstract:
    Macrophages are activated by a two-step mechanism involving at least two kinds of factors, a priming and a triggering factor, to become cytotoxic to various tumor cells. In the present study, we purified macrophage-activating factor for cytotoxicity I (MAF-C I), defined as a priming macrophage activating factor (MAF), by about 1,600-fold from the culture supernatant of a human T cell hybridoma, H3-E9-6, by a series of chromatographic procedures. We identified MAF-C I activity released from H3-E9-6 cells as interleukin-2 (IL-2) from the following findings. (i) The physicochemical properties of MAF-C I and IL-2 were almost identical. (ii) Purified MAF-C I active fraction also showed T cell proliferating activity. (iii) MAF-C I activity in the purified fraction was completely neutralized by anti-IL-2 antibodies. (iv) Human recombinant IL-2 (rIL-2), at a suboptimal dose, and lipopolysaccharide (LPS) synergistically induced monocyte-mediated cytotoxicity.
    [Abstract] [Full Text] [Related] [New Search]